Monograph Details
|
|
Respiratory Tract
> Rhinitis/rhinorrhea (intranasal products)
|
|
VERAMYST |
| Manufacturer |
|
GlaxoSmithKline Pharmaceuticals |
| Legal Classification |
|
Rx
|
| Pharmacological Class |
|
Steroid. |
| Generic Name |
|
Fluticasone furoate 27.5micrograms/spray; alcohol-free. |
| Indications |
|
Seasonal and perennial allergic rhinitis. |
| Children |
|
<2 years: not recommended. 2–11 years: initially 1 spray in each nostril once daily; may increase to 2 sprays in each nostril once daily. Maintenance: 1 spray in each nostril once daily. |
| Adults |
|
Initially 2 sprays in each nostril once daily. Maintenance: may reduce to 1 spray in each nostril daily. |
| Precautions |
|
Maintain regular regimen. Respiratory tract tuberculosis. Infection (eg, ocular herpes simplex). Severe hepatic impairment. Nasal surgery, ulcers, or trauma (may impair wound healing). If exposed to measles or chickenpox, consider anti-infective prophylactic therapy. If adrenal insufficiency exists following systemic corticosteroid therapy, replacement with topical corticosteroids may exacerbate symptoms of adrenal insufficiency. Monitor for growth suppression in children. Monitor for hypercorticism and HPA axis suppression (if occur discontinue gradually), candida infection or other nasal mucosal changes, vision changes. Avoid eyes. Pregnancy (Cat.C). Nursing mothers. |
| Interactions |
|
Avoid ritonavir. Caution with potent CYP3A4 inhibitors (eg, ketoconazole). |
| Adverse Reactions |
|
Headache, epistaxis, nasopharyngitis, pharyngolaryngeal pain, nasal ulceration, back pain, pyrexia, cough. |
| How Supplied |
|
Spray—10g (120 sprays) |
|
|
|
|
